

**Complete listing of claims:**

1. (currently amended) A method of improving the pharmacokinetic profile of administering a drug for which the major clearance mechanism in humans is CYP2D6 mediated oxidative biotransformation, ~~or a pharmaceutically acceptable salt thereof,~~ comprising administering an effective amount of the drug in combination with a CYP2D6 inhibitor, or a pharmaceutically acceptable salt thereof, to a human in need of the intended pharmaceutical activity of such drug, wherein said drug and said CYP2D6 inhibitor are not the same compound, wherein said drug is (1S, 2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol or a pharmaceutically acceptable salt thereof.
2. (cancelled)
3. (cancelled)
4. (Original) A method according to claim 1, wherein the CYP2D6 inhibitor is quinidine, ajmalacine or pharmaceutically acceptable salts thereof.
5. (Original) A method according to claim 1, wherein the CYP2D6 inhibitor is selected from the group consisting of sertraline, venlafaxine, dexmedetomidine, triptennelamine, premethazine, hydroxyzine, halofrantane, chloroquine, moclobemide, and pharmaceutically acceptable salts thereof.
6. (Original) A method according to claim 1, wherein the CYP2D6 inhibitor is St. John's wort, or an extract of constituent thereof.